ALND vs RDT in Positive Sentinel Node After Neoadjuvant Therapy
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Axillary Adenopathy
- Breast Cancer
- Radiotherapy Side Effect
- Therapy-Associated Cancer
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: A prospective, randomized, multicenter study.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
A prospective, randomized, open-label, parallel-assigned, multicenter, phase III study. The estimated sample size is 1.666 patients, over 5 years. Patients will be stratified and analyzed independently according to the neoadjuvant treatment regimen, whether chemotherapy (CT) +/- hormonal therapy (HT...
A prospective, randomized, open-label, parallel-assigned, multicenter, phase III study. The estimated sample size is 1.666 patients, over 5 years. Patients will be stratified and analyzed independently according to the neoadjuvant treatment regimen, whether chemotherapy (CT) +/- hormonal therapy (HT).
Tracking Information
- NCT #
- NCT04889924
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Maria Laplana, MD Institut Catala de Oncologia Principal Investigator: Amparo Garcia-Tejedor, MDPhD Hospital Universitari de Bellvitge
Get Well Soon